Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Treatment Type
3.2. Market Snippet by End-User
3.3. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Development of technically advanced products and solutions for treatment of plantar fasciitis
4.1.1.2. Rising cases of plantar fasciitis couple with increasing obesity
4.1.1.3. XX
4.1.2. Restraints:
4.1.2.1. High cost of treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Epidemiology
5.2. Pipeline Analysis
5.3. Porter’s Five Forces Analysis
5.4. Supply Chain Analysis
5.5. Clinical Trials
5.6. Pricing Analysis
5.7. Regulatory Analysis
5.8. Reimbursement Analysis
5.9. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
7.3. Market Attractiveness Index, By Treatment Type Segment
7.3.1. Surgery*
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.2. Shockwave Therapy
7.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
7.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
7.3.3. Medication Therapy
7.3.3.1. Analgesics
7.3.3.1.1. Acetaminophen (Aspirin Free Anacin, Feverall, Tylenol)
7.3.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
7.3.3.2.1. Ibuprofen (Advil, Excedrin IB, Motrin, Ibuprin)
7.3.3.2.2. Ketoprofen (Actron, Orudis, Oruvail)
7.3.3.2.3. Naproxen (Aleve, Anaprox, Naprelan, Naprosyn)
7.3.3.3. Others
7.3.4. Orthotics
7.3.5. Other treatments
8. By End-User
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
8.3. Market Attractiveness Index, By End-User Segment
8.3.1. Hospitals*
8.3.1.1. Introduction
8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3.2. Orthopedic Clinics
8.3.3. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. U.K.
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Pfizer, Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Shapecrunch Technology Pvt Ltd
11.3. Hanger, Inc.
11.4. A. Algeo Limited
11.5. Bauerfeind AG
11.6. Ottobock SE & Co. KGaA (Ottobock Holding)
11.7. GlaxoSmithKline plc
11.8. Sanofi
11.9. Bayer Group (Dr. Scholl’s)
11.10. Superfeet Worldwide, Inc.(*LIST NOT EXHAUSTIVE)
12. Premium Insights
13. DataM Intelligence
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us